Lung Cancer

The AJMC^® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Heather Wakelee, MD

Considerations for Immunotherapy Duration in NSCLC: Dr Heather Wakelee

September 11th 2024

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Diverse representation in health care materials is one of multiple factors that could benefit patient education initiatives | image credit: Fitry - stock.adobe.come

Different Options for Different People: Dr Bellinda King-Kallimanis Explores the State of Patient Education in Lung Cancer

September 10th 2024

Sandip Patel, MD

Dr Sandip Patel Previews the Highly Anticipated 50th Anniversary of WCLC

September 6th 2024

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com

Late-Stage Vibostolimab, Pembrolizumab Plus Chemotherapy Trial Discontinued Due to Adverse Events

By Julia Bonavitacola

August 8th 2024

AJMC

Shared Decision-Making for Lung Cancer Screening: More Straw for the Camel’s Back

By Jonas B. Green, MD, MPH, MSHS

May 31st 2024

Key Updates in the Management of Small Cell Lung Cancer

Explore recent advances in small cell lung cancer management, including staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery with this Peer Exchange.

Explore recent advances in small cell lung cancer management, including staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery with this Peer Exchange.

More News

Genomic Profiling for Mutations

February 16th 2021

FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC

The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.

Lung Cancer

February 16th 2021

Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show

A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.

A NSCLC tumor surrounded by metabolites involved in the hexosamine biosynthesis pathway.

February 16th 2021

Possible Treatment Identified for Aggressive NSCLC Subset

Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.

Lung Cancer Screening

February 15th 2021

Lung Cancer Screenings Fall, Biopsy Rates Rise During COVID-19

Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.

FDA Grants Tiragolumab Breakthrough Therapy Designation

February 15th 2021

FDA Grants Tiragolumab Breakthrough Therapy Designation for PD-L1–High NSCLC

Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.

What We’re Reading: More Americans Vaccinated Than Infected; US Funds Rapid OTC COVID-19 Tests; Breast Most Common Cancer Worldwide

February 2nd 2021

What We’re Reading: More Americans Vaccinated Than Infected; US Funds Rapid OTC COVID-19 Tests; Breast Most Common Cancer Worldwide

More Americans have received at least 1 dose of a coronavirus disease 2019 (COVID-19) vaccine than have tested positive for the virus; Biden administration funds mass production of a rapid over-the-counter COVID-19 test; breast cancer surpasses lung cancer as most common cancer worldwide.

Lungs

January 23rd 2021

First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC

Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable.

Examining Lung Scan

January 14th 2021

Study Finds No Association Between Autoimmune Disease and Lung Cancer Survival

Patients with both lung cancer and autoimmune disease have no significant difference in survival than patients with lung cancer alone, according to recent research from Northwestern University.

Doctor Looking at Scan

January 13th 2021

ACS Cancer Statistics Report Shows Record Drop in Cancer Mortality, But Persistent Disparities

The 2021 American Cancer Society annual Cancer Statistics report found that the overall rate of cancer mortality continuously declined from 1991 to 2018 but also highlighted racial and geographic disparities.

Joanna Thompson, Highlands Oncology Group

December 31st 2020

Joanna Thompson Discusses What Makes a Patient High Risk for Lung Cancer

There are several risk factors to review when determining whether or not a patient is high risk for lung cancer and should be screened, said Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.

The Top 5 Lung Cancer Stories of 2020

December 27th 2020

The Top 5 Most-Read Lung Cancer Stories of 2020

This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.

COVID-19 Vaccines

December 21st 2020

COVID-19 Vaccine Considerations for the Immunocompromised

FDA fact sheets on coronavirus disease 2019 (COVID-19) vaccines provide guidelines for special patient populations, including the immunocompromised.

Lung Cancer

December 17th 2020

Immunotherapy Side Effects and OS in NSCLC

NSCLC patients who developed immune-related adverse events during immunotherapy showed longer overall survival and progression-free survival than patients who did not.

Lung Health

December 11th 2020

Women Have Lower Mortality Than Men After Lung Cancer Surgery

Women had higher survival rates after lung cancer compared with men, regardless of other risk factors, in a population-based registry study from the Karolinska Instituet in Sweden.

Joanna Thompson, Highlands Oncology Group

December 10th 2020

Joanna Thompson on Engaging With PCPs for a Successful Lung Cancer Screening Program

Highlands Oncology Group has found the most success getting the word out about its lung cancer screening program by directly engaging with primary care physicians (PCPs), said Joanna Thompson of Highlands Oncology Group.

Lung Cancer

December 4th 2020

Janssen Seeks FDA Approval of Amivantamab for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

Data from the Phase I CHRYSALIS trial also support an expanded access program that makes some patients eligible for amivantamab treatment while the FDA reviews the submission.

Drug Administration

November 25th 2020

The Importance of Cancer Clinical Trials, Even in a Pandemic

Physicians and patient advocates alike are working to spread the message that it is safe to continue on the course of cancer care and participate in clinical trials during COVID-19.

Joanna Thompson, Highlands Oncology Group

November 22nd 2020

Joanna Thompson Outlines How Highlands Oncology Group Screens for Lung Cancer

The Highlands Oncology Group partners with primary care providers to identify patients at high risk of lung cancer so the specialists can do a more in-depth screening, explained Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.

Lung Cancer

November 20th 2020

First-Line Lorlatinib Improves PFS in ALK-Positive NSCLC

Early treatment with lorlatinib led to improved progression-free survival in ALK-positive NSCLC patients compared with crizotinib treatment, a study published in the New England Journal of Medicine found.

Cost Savings at Multidisciplinary Lung Clinics

November 18th 2020

Multidisciplinary Lung Cancer Clinic Saves Patients, System Costs

Multidisciplinary lung cancer clinics might help patients and the system save on treatment costs while improving patient experiences, according to an abstract presented at CHEST 2020.

Contributor: Links Between COVID-19 Comorbidities, Mortality Detailed in FAIR Health Study

November 11th 2020

Contributor: Links Between COVID-19 Comorbidities, Mortality Detailed in FAIR Health Study

Robin Gelburd, JD

In patients under age 70, lung cancer conferred the highest risk of death from coronavirus disease 2019 (COVID-19).

Lung Cancer Screening

November 9th 2020

Lung Cancer Screening Criteria Miss Young, High-Risk Black Smokers

Current lung cancer screening guidelines do not identify high-risk young, African American smokers, an abstract presented at CHEST 2020 found.

Lung Cancer Screenings

November 4th 2020

Can Emphasis on Education Increase Lung Cancer Screenings?

Abstracts presented at CHEST 2020 explored possible reasons for low lung cancer screening rates and suggested solutions.

Lung illustration

November 3rd 2020

Libtayo Accepted for FDA Priority Review in NSCLC With PD-L1 Expression

Regeneron’s PD-1 inhibitor Libtayo was accepted for priority FDA review for the treatment of first-line locally advanced or metastatic non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.

Lung Cancer Screenings for Women

October 31st 2020

Lung Cancer in Women: More Risk, Less Attention

Current screening criteria in the United States identify fewer women than men who will get lung cancer, creating a perfect storm for what experts during a session at the CHEST Annual Meeting deemed an “invisible epidemic.”

Non-Small Cell Lung Cancer

October 29th 2020

KRAS G12C Inhibitor Shows Promising Effects in NSCLC, Other Solid Tumors

A pair of abstracts based on a phase 1/2 trial of adagrasib (MRTX849) a KRAS G12C inhibitor, showed promising results for patients with lung, bowel, and other solid tumors, researchers reported at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

Non-Small Cell Lung Cancer Outcomes With Pembrolizumab Plus Radiation

October 23rd 2020

Pembrolizumab Plus Radiation Therapy Improves NSCLC Outcomes, Study Finds

Researchers analyzed 2 randomized studies to learn how adding radiation therapy to pembrolizumab immunotherapy affects non-small cell lung cancer patient outcomes.

Woman Consulting With a Doctor

October 22nd 2020

Cancer Care Delays in COVID-19 Could Lead to Higher Morbidity, Mortality

Cancer screenings and treatments saw a sharp decline during the early months of the pandemic. The authors of a new study on the delays in care warn that the fallout may be grim.

Propelled by Targeted Therapies, NSCLC Mortality Fell Between 2013 to 2016

October 17th 2020

Propelled by Targeted Therapies, NSCLC Mortality Fell Between 2013 to 2016

Allison Inserro

Nearly 10,000 deaths from non–small-cell lung cancer (NSCLC) were likely delayed between 2014 to 2016, the researchers calculated.

Nivolumab Meets Primary Endpoint in Resectable NSCLC

October 16th 2020

Nivolumab Meets Primary Endpoint in Resectable NSCLC

The safety profile of nivolumab plus chemotherapy was also consistent with previously reported studies in NSCLC, the researchers said.

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions